All In Biotech

Drug Trial Radar · NCT04910568

A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma

An Open-Label, Multicenter, Phase Ib Trial Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab as Monotherapy and Cevostamab Plus Pomalidomide and Dexamethasone or Cevostamab Plus Daratumumab and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 186 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

186

Planned (sponsor's estimate)

Start

Jul 26, 2021

Primary completion

Dec 21, 2028

Study completion Dec 21, 2028

Sponsor

Lead sponsor
Genentech, Inc.Roche (Genentech) (RHHBY)
Sponsor type
Industry
Collaborators
Hoffmann-La Roche
First posted
Jun 2, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase Ib, multicenter, open-label study will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of cevostamab monotherapy, cevostamab plus pomalidomide and dexamethasone (Pd) or cevostamab plus daratumumab and dexamethasone (Dd) which will be administered to participants with relapsed or refractory multiple myeloma (R/R MM) via intravenous (IV) infusion.

Conditions

  • Multiple Myeloma

Interventions

  • CevostamabDrug

    Cevostamab will be administered intravenously on a 28-day cycle, up to a total of 13 cycles (Arm A), in 28-day cycles Q2W followed by Q4W (Arm B) and in 21 day cycles from C1-C8 Q3W and 28-day cycles from C9 onwards Q4W (Arm C). For Arm A, participants have the option to enter re-treatment within 12 months of the end of treatment visit. For Arms B and C, participants can be treated until disease progression or unacceptable toxicity.

  • TocilizumabDrug

    Tocilizumab will be administered for the treatment of cytokine release syndrome (CRS) when necessary.

  • PomalidomideDrug

    Pomalidomide will be administered orally (PO) on a 28-day cycle.

  • DaratumumabDrug

    Daratumumab will be administered subcutaneously (SC) on 21 day (C1-8) and 28-day cycles (C9 onwards).

  • DexamethasoneDrug

    Arm A: Dexamethasone will be administered as a premedication. Arms B and C: Dexamethasone will be administered via IV or orally at 20 mg as study investigational medicinal product.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Recommended Phase II Dose (RP2D)Time frame: Baseline up to approximately 4 years
  2. Percentage of Participants with Adverse EventsTime frame: Baseline up to approximately 4 years
  3. Percentage of Dose InterruptionsTime frame: Baseline up to approximately 4 years
  4. Percentage of Dose ReductionsTime frame: Baseline up to approximately 4 years
  5. Percentage of Dose IntensityTime frame: Baseline up to approximately 4 years
  6. Percentage of Treatment DiscontinuationTime frame: Baseline up to approximately 4 years

Locations

34 sites in 13 countries. Site status is shown where the registry gives one.

  • City of Hope

    Duarte, California · Recruiting

  • City of Hope - Lennar Foundation Cancer Center

    Irvine, California · Recruiting

  • Colorado Blood Cancer Institute (CBCI) at Presbyterian/ St. Luke's Medical Center

    Denver, Colorado · Recruiting

  • Winship Cancer Institute

    Atlanta, Georgia · Withdrawn

  • Karmanos Cancer Institute.

    Detroit, Michigan · Completed

  • Washington University School of Medicine

    St Louis, Missouri · Recruiting

  • Peter MacCallum Cancer Centre

    Melbourne, Victoria, Australia · Active not recruiting

  • The Alfred Hospital

    Melbourne, Victoria, Australia · Recruiting

  • Cross Cancer Institute

    Edmonton, Alberta, Canada · Active not recruiting

  • Hamilton Health Sciences

    Hamilton, Ontario, Canada · Active not recruiting

  • University Health Network

    Toronto, Ontario, Canada · Active not recruiting

  • Fakultni Nemocnice Ostrava

    Ostrava, Czechia · Active not recruiting

  • I Interni klinika

    Prague, Czechia · Withdrawn

  • Rigshospitalet

    København Ø, Denmark · Active not recruiting

  • Hôpital Saint-Louis

    Paris, France · Withdrawn

  • CHU de Poitiers - La Miletrie

    Poitiers, France · Active not recruiting

  • CHU Pontchaillou

    Rennes, France · Withdrawn

  • Rambam Medical Center

    Haifa, Israel · Active not recruiting

  • Sourasky Medical Centre

    Tel Aviv, Israel · Recruiting

  • Asst Papa Giovanni Xxiii

    Bergamo, Lombardy, Italy · Active not recruiting

  • A.O. Spedali Civili Di Brescia-P.O. Spedali Civili

    Brescia, Lombardy, Italy · Completed

  • Nagoya City University Hospital

    Aichi, Japan · Withdrawn

  • National Hospital Organization Okayama Medical Center

    Okayama, Japan · Withdrawn

  • The Cancer Institute Hospital of JFCR

    Tokyo, Japan · Withdrawn

  • Yamagata University Hospital

    Yamagata, Japan · Active not recruiting

  • Uniwersyteckie Centrum Kliniczne

    Gdansk, Poland · Withdrawn

  • Pratia Onkologia Katowice

    Katowice, Poland · Active not recruiting

  • Uniwersytecki Szpital Kliniczny w Poznaniu

    Późna, Poland · Withdrawn

  • Seoul National University Hospital

    Seoul, South Korea · Recruiting

  • Samsung Medical Center

    Seoul, South Korea · Recruiting

  • Hospital Universitari Vall d'Hebron

    Barcelona, Spain · Recruiting

  • Hospital General Universitario Gregorio Marañon

    Madrid, Spain · Recruiting

  • University College London Hospitals NHS Foundation Trust

    London, United Kingdom · Recruiting

  • Royal Marsden Hospital

    Sutton, United Kingdom · Active not recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.